Triptorelin is a GnRH agonist. It is filed in this library under sexual & reproductive, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Triptorelin has an FDA-approved product on the U.S. market, marketed as Trelstar under application NDA020715.
The current label is held by Verity Pharmaceuticals Inc.
From the FDA label
is indicated for the treatment of advanced prostate cancer [ see Clinical Studies ].Quoted from the FDA-approved prescribing information
The evidence
One source on Triptorelin, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.
Nearby
Markers on this pathway
Triptorelin's FDA-approved label indicates it for a condition managed by suppressing or controlling gonadotropin release. These are the markers clinicians use when assessing the pituitary-gonadal axis. They are listed here so you can read about them, not as a statement that Triptorelin changes any of them.
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Triptorelin. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides